Evidence: US Healthcare, Third Leading Cause of Death_Institute of Medicine, JAMA, 2000
Click here for full article
Click here for full article
Patient vs. Portfolio: ImClone_Salon December 9, 2002 Salon.com looks at how conflicts of interest impact on patients who are recruited to serve as subjects of clinical drug trials. “Patients affected by the ImClone scandal have been lost in the media’s rush to cover the tale of Martha Stewart and other…
The extraordinary story of how patient access to COVID treatments was denied, eventually involving a witch hunt of physicians who dared to treat patients by Meryl Nass, MD.[Dr. Nass is a member of the Alliance for Human Research Protection Board of Directors.] First came the Chloroquine and Hydroxychloroquine suppression In…
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
In essence FDA proposals merely change the seating arrangement on the deck of the sinking Titanic. Eli Lilly announced that it intends to seek FDA approval for a long-lasting injectable form of Zyprexa (taken once a month).
The pharmaceutical industry’s latest antidepression drug marketing campaign is being launched with collaboration of the National Institute of Mental Health (NIMH)—
Pfizer’s smoking cessation drug, Chantix (varenicline), may be the most dangerous drug ever to carry the government seal of approval–it poses a danger, not just to those who ingest the drug, but to people in the community in which they live.